Navigation Links
CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain

HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGenix, Inc. (CYGX.OB) announced today that Dr. Yin Chen, Chief Scientific Officer will present an update on preclinical animal data for DNA vaccines made using the Company's proprietary synDNA(TM) technology at the 2007 DNA Vaccines conference to be held in Malaga, Spain between May 23 and May 25.

Dr. Chen comments, "We have successfully conducted tests of synDNA(TM) based vaccines in mice, rabbits and non-human primates. The data to be presented will demonstrate the stimulation of the immune response comparing synDNA(TM) based vaccines to traditional plasmid DNA vaccines designed for the prevention of seasonal flu, HIV, smallpox and Hepatitis B. The tests indicate that the immune response triggered by synDNA(TM) vaccines is comparable to, and in some cases more effective than responses mediated by plasmid DNA. Data will also be shown demonstrating the effectiveness of a novel vaccine that protects against a highly virulent form of avian (bird) flu in animal challenge studies. These challenge experiments demonstrated that synDNA(TM) is just as effective as plasmid in mediating a protective immune response when the host is attacked by virulent viruses.

Malcolm Skolnick, CEO, states, "DNA vaccines have proven to be a potent means of providing protective immunity against viruses, bacteria and parasites in many species from fish to primates. Our animal tests demonstrate that DNA vaccines made with synDNA(TM) technology are not only effective in eliciting robust immune responses, but also provide protection against dangerous pathogens. Presentation of our data at the DNA vaccine conference is a great opportunity to showcase and discuss our work with other experts in this field including major pharmaceutical and biotech companies."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA(TM) production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of therapeutic DNA inside the cell. CytoGenix currently holds 11 granted patents and about 49 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at


CytoGenix, Inc., Houston
Media Contact:
Pam Schertz, 713-789-0070


Related medicine technology :

1. CytoGenix Announces Successful Testing of synDNA Vaccine for Avian Influenza Virus
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):